This letter refutes the “overdiagnosis” narrative, blaming the stimulant shortage on DEA regulatory failures, clinical constraints, and recognition of historical underdiagnosis. By concluding that ...
This post is sponsored by Claudia Mills. The review and opinions expressed in this post are based on my personal views. About ...